23andMe Holding Co. - ME STOCK NEWS

The independent directors of 23andMe Holding Co. (Nasdaq: ME) have resigned from the Board, effective immediately. In a letter to CEO Anne Wojcicki, they cited the lack of a fully financed, fully diligenced, actionable proposal that benefits non-affiliated shareholders, despite months of work. The directors expressed their unwillingness to consider further extensions and noted differences in strategic direction for the company.

The resignation comes after 5 months of no notable progress on such a proposal. The directors acknowledged Wojcicki's concentrated voting power and decided to resign to avoid a protracted and distracting difference of view. They expressed continued support for the company's mission and belief in its personalized health and wellness offering, while also recognizing their pride in 23andMe's achievements in pioneering direct access to genetic information.

23andMe (Nasdaq: ME) announced positive nonclinical data for its first-in-class antibody 23ME-01473 at the ESMO Congress 2024. The antibody, targeting the NKG2D ligand ULBP6, showed inhibition of tumor growth in a non-small cell lung cancer mouse model. Elevated levels of ULBP6 were confirmed in squamous cell carcinomas and some adenocarcinomas, guiding potential clinical indications. The ongoing Phase 1/2a trial, which began in March 2024, has prioritized four expansion cohort cancer types: head and neck squamous cell carcinoma, squamous non-small cell lung cancer, colorectal cancer, and triple-negative breast cancer. This data supports the potential of human genetics in identifying new targets for immuno-oncology drug development.

23andMe (Nasdaq: ME) announced positive preliminary Phase 2 safety and efficacy data for 23ME-00610, a first-in-class anti-CD200R1 antibody, at the ESMO Congress 2024. Key findings include:

1. A confirmed partial response in a patient with refractory clear-cell renal-cell carcinoma (ccRCC).
2. Acceptable safety and tolerability profile.
3. Higher tumor expression of CD200 may be associated with clinical benefit.
4. Potential effectiveness in 'cold' tumors, suggesting opportunity for patients unable to benefit from PD-1/PD-L1 checkpoint inhibitors.

The study included 10 ccRCC patients and 13 patients with TMB-H or MSI-H cancers. The data suggests that interrupting the CD200/CD200R1 pathway has potential to reverse immune suppression in the tumor microenvironment.

23andMe, in collaboration with the National Human Genome Research Institute and Johns Hopkins University, conducted one of the largest and most diverse studies on sickle cell trait (SCT) and its association with venous thromboembolism (VTE). The study, published in Blood Advances, analyzed data from 4.2 million research-consented participants, including 19,000 with SCT.

Key findings include:

• SCT is a modest risk factor for blood clots across diverse populations
• Individuals with SCT have a lower risk of VTE compared to carriers of factor V Leiden
• SCT is associated with pulmonary emboli (PE) but not deep vein thrombosis (DVT)
• The study suggests a unique mechanism of blood clotting in people with SCT

This research provides valuable information for clinicians counseling individuals with SCT and highlights the importance of inclusive genetic research.

23andMe (Nasdaq: ME) will present updates on its clinical immuno-oncology programs at the ESMO Congress 2024 in Barcelona. The company will showcase three posters on 23ME-00610, a first-in-class anti-CD200R1 antibody, and two on 23ME-01473, an anti-ULBP6 monoclonal antibody.

Key highlights include:

• Preliminary efficacy data for 23ME-00610 in renal cancer and TMB-H/MSI-H cohorts
• Analysis of CD200 as a potential biomarker for 23ME-00610 efficacy
• Preclinical data on 23ME-01473 and its ongoing Phase 1/2a dose escalation study

Both drug candidates were discovered using 23andMe's proprietary database of human genetic and health information, leveraging data from over 15 million genotyped customers.

Lemonaid Health, a subsidiary of 23andMe (Nasdaq: ME), is now offering GLP-1 medications including Ozempic®, Wegovy®, and compounded semaglutide through a weight loss program on its telehealth platform. The program provides a $49 monthly membership with access to clinician consultations, prescriptions, and ongoing support. Medication costs start at $299 per month for compounded semaglutide.

Concurrently, 23andMe launched a study to investigate the genetic factors influencing GLP-1 effectiveness and side effects. The company aims to uncover insights for personalized weight loss treatments and preventive health strategies. GLP-1 medications have shown potential benefits beyond weight loss, including treatment of type 2 diabetes, heart disease, and possibly Parkinson's, arthritis, Alzheimer's, and sleep apnea.

23andMe (NASDAQ:ME) faced a major data breach in December 2023, affecting approximately 7 million users. A class action lawsuit reveals that hackers specifically targeted Jewish and Chinese customers, compiling and selling their personal genetic information on the dark web. The breach included a leak of over 1 million Jewish customers and 350,000 Chinese customers. The company allegedly concealed these details when notifying affected users. The lawsuit claims 23andMe has not informed compromised customers about the specific targeting or the dark web disclosure. The hacked data included genetic heritage, names, addresses, phenotype and health information, photos, and identification data.

23andMe (NASDAQ: ME) faced a significant data breach in December 2023, affecting approximately 7 million users of its genetic services website. A recently filed class complaint reveals that hackers specifically targeted the personal genetic information of Jewish and Chinese customers. The breach resulted in the compilation and sale of sensitive data on the dark web, including a list of over 1 million Jewish customers and 350,000 Chinese customers. The lawsuit alleges that 23andMe concealed these details when notifying affected customers and has not informed them about the specific targeting or the extent of the data exposure on the dark web.

23andMe (NASDAQ:ME) faced a significant data breach in December 2023, affecting approximately 7 million users of its genetic services website. A recently filed class complaint alleges that hackers specifically targeted the personal genetic information of Jewish and Chinese customers, compiling and selling this data on the dark web. The breach reportedly included a list of over 1 million Jewish customers and 350,000 Chinese customers. The lawsuit claims 23andMe has not fully informed affected customers about the extent of the breach or the targeted nature of the attack. The disclosure poses potential safety risks, particularly for Chinese citizens. Legal action is being pursued for affected individuals, especially those with Ashkenazi Jewish heritage or Chinese ancestry in specific states.